Cantargia and BioWa have signed an extension of the licence agreement around the BioWa proprietary POTELLIGENT technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
Gilead Sciences has finalised its 10-year global research and development deal, worth up to $5.05bn (£4.11bn), with Belgium-based Galapagos following regulatory clearances.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53m (£43.38m) Series C financing.
US-based Oncorus has raised $79.5m (£65.56m) in a Series B financing round co-led by Cowen Healthcare Investments and Perceptive Advisors.
Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million (£66m) Series C financing.
Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202m (£166m) with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
Caisse de dépôt et placement du Québec (CDPQ), a Canadian long-term institutional investor, has agreed to make a minority investment of $500m (£413.8m) in Mexican pharmaceutical company Sanfer.
Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.
GeneCentric Therapeutics announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.
Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60m (£49.7m) Series B financing round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.